Verbatim response from Perplexity
Usually, no—compounded GLP-1s are not the best default option when Wegovy is denied, because they are not FDA-approved, are not reviewed for safety/effectiveness/quality before sale, and can have variable quality or fraudulent labeling.[6][1][5] They can be a fallback in some situations, especially when you can’t access an FDA-approved product, but they should be used only with a prescriber and a carefully vetted pharmacy.[6][5][8]
What the evidence and regulators suggest:
- FDA-approved Wegovy is preferred when you can get it, because it has the strongest evidence for consistency and safety.[3][1]
- Compounded semaglutide is not the same as Wegovy and is not a generic version; FDA-approved generics do not exist yet.[1]
- The FDA says compounded drugs may be appropriate only when a patient’s medical need cannot be met by an FDA-approved drug or the FDA-approved drug is not commercially available.[6]
- The market for compounded GLP-1s has also become less reliable as shortages have eased and compounding tied to shortage status has come under pressure.[2][4]
What to consider instead of jumping straight to compounded GLP-1s:
- Appeal the insurance denial with your clinician, especially if you meet Wegovy criteria.
- Ask about manufacturer savings programs or cash-pay options for branded drugs; some patients can access Wegovy at reduced out-of-pocket cost, though these are often temporary.[5][2]
- Ask your prescriber about other FDA-approved obesity medications if Wegovy remains inaccessible.
- If you still consider compounded therapy, choose a licensed, accredited compounding pharmacy and avoid products with extra “add-ons” unless your clinician has a specific reason.[5][4]
If you want, I can help you compare Wegovy appeal vs compounded semaglutide vs other FDA-approved weight-loss medications based on cost, safety, and access.